Potential repurposing of the HDAC inhibitor valproic acid for patients with COVID-19.
Eur J Pharmacol
; 898: 173988, 2021 May 05.
Artículo
en Inglés
| MEDLINE | ID: covidwho-1116626
ABSTRACT
There is a need for therapeutic approaches to prevent and mitigate the effects of Coronavirus Disease (2019) (COVID-19). The histone deacetylase (HDAC) inhibitor valproic acid, which has been available for the therapy of epilepsy for many years, is a drug that could be repurposed for patients with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection. This article will review the reasons to consider valproic acid as a potential therapeutic to prevent severe COVID-19. Valproic acid could reduce angiotensin-converting enzyme 2 and transmembrane serine protease 2 expression, required for SARS-CoV-2 viral entry, and modulate the immune cellular and cytokine response to infection, thereby reducing end-organ damage. The combined anti-thrombotic, anti-platelet, and anti-inflammatory effects of valproic acid suggest it could be a promising therapeutic target for COVID-19.
Palabras clave
Texto completo:
Disponible
Colección:
Bases de datos internacionales
Base de datos:
MEDLINE
Asunto principal:
Inhibidores de Agregación Plaquetaria
/
Ácido Valproico
/
Inhibidores de Histona Desacetilasas
/
Fibrinolíticos
/
SARS-CoV-2
/
Tratamiento Farmacológico de COVID-19
/
Antiinflamatorios
Límite:
Animales
/
Humanos
Idioma:
Inglés
Revista:
Eur J Pharmacol
Año:
2021
Tipo del documento:
Artículo
País de afiliación:
J.ejphar.2021.173988
Similares
MEDLINE
...
LILACS
LIS